Sonoma Pharmaceuticals (NASDAQ: SNOA) is a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique, affordable differentiated therapies and branded prescription products to improve the lives of patients with dermatologic diseases and conditions and advanced tissue care needs. The Company’s products, which are sold throughout the United States and in 39 countries around the world, have improved patient outcomes for more than five million patients globally by treating and reducing certain topical skin diseases and conditions including acne, atopic dermatitis, scarring, infections, itch, pain, odor and harmful inflammatory responses. The Company’s headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. In 2013, with a new Board of Directors and new management team, the Company pivoted to focus on one specialty pharmaceutical area, medical dermatology, and created their own sales force in the United States to promote their unique, affordable, differentiated prescription dermatology products. Their customer base includes hospitals, medical centers, doctors, pharmacies, distributors and wholesalers. The Company sells products directly to end users and to distributors. The Company also licenses its technology and products.